Biotech Values

[WorstLuck]

Neither of those acquired companies had especially good drugs, IMO, but Guyer is evidently an adept dealmaker.

The EyeBio drug is interesting. They had a very small and short P1b/2a that reported the kind of results RZLT would have loved to have gotten.

Not sure what MRK is up to here. It's a monthly injectable in a world that is going to longer lasting treatment and generic Eyelea as competition? Maybe they intend to change the delivery to a sustained release, IDK.